Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + FLAMSA-Treosulfan Conditioning Before Allogeneic HSCT in MDS/CMML/sAML
2024-514688-24-00Phase 2Authorised
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Maximal organ toxicity and number of Grade III or higher adverse events to day +30. Planned start Jul 2024; status: authorised.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-514688-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514688-24-00.